Enterprise Value

-4.871M

Cash

25.24M

Avg Qtr Burn

-4.347M

Short % of Float

0.10%

Insider Ownership

0.78%

Institutional Own.

7.95%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Rigosertib + Pembrolizumab Details
Melanoma, Skin cancer, Cancer

Phase 2

Data readout

Rigosertib (RAS inhibitor) Details
Cutaneous squamous cell carcinoma, Solid tumor/s, Cancer

Phase 2

Update

Rigosertib + Nivolumab Details
Cancer, Non-small cell lung carcinoma

Phase 1/2

Data readout

Narazaciclib + letrozole Details
Solid tumor/s, Cancer, Endometrial cancer

Phase 1/2

Data readout

Narazaciclib (ON 123300) (CDK4/6 & ARK5 inhibitor) Details
Cancer, Solid tumor/s, ER+/HER2- breast cancer, Breast cancer, Metastatic breast cancer

Phase 1

Update

Rigosertib Details
Myelodysplastic syndrome

Failed

Discontinued